Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Background The ongoing Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is having an enormous impact on society worldwide and is especially posing a threat to health in vulnerable patients, such as patients with immune deficien...

Descripción completa

Detalles Bibliográficos
Autores principales: Spanjaart, Anne Mea, Ljungman, Per, De La Camara, Rafael, Tridello, Gloria, Ortiz-Maldonado, Valentín, Urbano-Ispizua, Alvaro, Barba, Pere, Kwon, Mi, Caballero, Dolores, Sesques, Pierre, Bachy, Emmanuel, Di Blasi, Roberta, Thieblemont, Catherine, Calkoen, Friso, Mutsaers, Pim G.N.J., Maertens, Johan A., Giannoni, Livia, Nicholson, Emma, Collin, Matthew P., Vaz, Carlos Pinho, Metafuni, Elisabetta, Martínez-López, Joaquín, Dignan, Fiona, Ribera, Josep-Maria, Nagler, Arnon, Folber, František, Sanderson, Robin, Bloor, Adrian, Ciceri, Fabio, Knelange, Nina, Ayuk, Francis A., Kröger, Nicolaus, Kersten, Marie José, Mielke, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
704.Cellular Immunotherapies: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701531/
http://dx.doi.org/10.1182/blood-2021-149466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701531/
http://dx.doi.org/10.1182/blood-2021-149466

Ejemplares similares